Roche reject recycled for ophthalmic indication
An antibody that Roche licensed from Genmab for oncology indications, pursued into Phase II, then dropped two years ago, is restarting clinical development in an ophthalmic indication.
An antibody that Roche licensed from Genmab for oncology indications, pursued into Phase II, then dropped two years ago, is restarting clinical development in an ophthalmic indication.